Plain-English translation of NCT01106794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is collecting tissue samples, spinal fluid, blood, and urine from children diagnosed with diffuse intrinsic pontine glioma (DIPG) and other brainstem tumors. Researchers will examine these samples at the molecular and genetic level to understand what causes these tumors to form and grow. By identifying the unique genetic abnormalities in these tumors, doctors hope to find new targets for developing more effective treatments.
Brainstem tumors like DIPG are extremely serious childhood cancers with no current effective treatments. This study exists because researchers need to understand the genetic makeup of these tumors to design new, targeted therapies that could save children's lives.
You likely qualify if…
You likely don't qualify if…
If your child qualifies, researchers will collect samples during their treatment and/or at other medical appointments. Samples may include tumor tissue obtained during surgery or biopsy, spinal fluid, blood, and urine. These samples will be studied in the laboratory to identify genetic patterns and abnormalities. There is no medication to take as part of this study—it is purely a sample collection and research effort.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Enrollment target
~100 participants
Started
April 2010
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Javad Nazarian, PhD
Children's National Research Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.